Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.

FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.

UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.

Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.

Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.

Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.

Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.

APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.